Table 3.
Stroke scores and laboratory parameters according to mortality status in female patients with ischemic stroke.
| Mortality (n = 134) | Non-mortality (n = 599) | p-value | |
|---|---|---|---|
| NIHSS | 17.21 ± 7.09 (1–35) | 6.19 ± 5.48 (0–25) | 0.001*a |
| GCS | 10.29 ± 3.45 (3–15) | 14.42 ± 1.33 (7–15) | 0.001*a |
| SEDAN score | 2.91 ± 1.16 (0–6) | 1.84 ± 1.15 (0–6) | 0.001*a |
| THRIVE score | 5.07 ± 1.64 (0–9) | 2.79 ± 1.65 (0–8) | 0.001*a |
| mRS | 4.60 ± 0.83 (1–5) | 2.69 ± 1.63 (0–5) | 0.001*a |
| Blood glucose (mg/dL) | 169.71 ± 88.54 (75–718) | 152.61 ± 74.67 (71–558) | 0.009*a |
| Creatinine (mg/dL) | 1.06 ± 0.56 (0.39–3.69) | 0.88 ± 0.57 (0.34–6.26) | 0.001*a |
| Hemoglobin (g/dL) | 12.26 ± 1.68 (8.20–16.90) | 12.65 ± 1.72 (4.6–21.9) | 0.020*a |
| Leukocyte (K/uL) | 11.14 ± 5.23 (2.50–40.10) | 9.00 ± 5.08 (1.4–107.8) | 0.001*a |
| Urea (K/uL) | 58.94 ± 28.04 (16–165) | 44.11 ± 23.34 (11–228) | 0.001*a |
| Albumin (g/dL) | 2.94 ± 0.61 (1.5–4.30) | 3.40 ± 0.50 (1.8–4.4) | 0.001*a |
| C-reactive protein (mg/dL) | 92.58 ± 98.71 (2.2–470.0) | 41.38 ± 66.58 (0.3–476) | 0.001*a |
| LDL-cholesterol (mg/dL) | 114.80 ± 33.13 (59–191) | 126.25 ± 41.09 (37–301) | 0.150a |
| HDL-cholesterol (mg/dL) | 44.92 ± 16.59 (20–91) | 42.68 ± 10.58 (17–96) | 0.643a |
| Triglyceride (mg/dL) | 143.50 ± 58.01 (49–330) | 160.59 ± 93.67 (40–627) | 0.052a |
| Treatment (n, %) | |||
| IV thrombolysis | 15 (11.2) | 32 (5.3) | 0.841b |
| Endovascular thrombectomy | 11 (8.2) | 25 (4.2) | |
| IV thrombolysis and thrombectomy | 16 (11.9) | 28 (4.7) | |
NIHSS, NIH stroke score; GCS, Glasgow coma score; mRS, Modified Rankin score; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; n, Number; IV, Intravenous.
*Statistical significance value.
aIndependent Sample T-test.
bChi-square (χ2) test.
Data are shown as mean ± SD (minimum–maximum) unless otherwise indicated.